The European Commission could issue fines to the world’s largest generic drug makers as early as next month, according to unnamed sources.
Leading generic firms Teva Pharmaceutical and Les Laboratoires Servier, along with other generic competitors, are under the Commission’s crackdown for alleged anticompetitive agreements made with brand name rivals, deals that are known as pay-for-delay schemes in which generic firms accept payment from brand name firms to delay the release of their cheaper, competing drugs.
Unnamed sources said Thursday that as many as six companies, including Teva and Servier, could be issued fines by the end of next month, before the Commission goes on vacation.
EU authorities first launched an inquiry into the pharmaceutical industry in 2008, leading to multiple antitrust investigations.
Full content: Bloomberg
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Shein Warns of Higher Costs for French Shoppers Amid EU Fee Proposal
May 22, 2025 by
CPI
DOJ Opens Antitrust Probe of Google’s AI Partnership with Character.AI
May 22, 2025 by
CPI
Google’s Unbundling Offer Puts Korean Regulators in Tight Spot
May 22, 2025 by
CPI
Justice Department and FTC Warn Common Ownership Could Breach Antitrust Law
May 22, 2025 by
CPI
South Africa Approves Canal+ MultiChoice Deal
May 21, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Industrial Policy
May 21, 2025 by
CPI
Industrial Strategy and the Role of Competition – Taking a Business Lens
May 21, 2025 by
Marcus Bokkerink
Industrial Policy, Antitrust, and Economic Growth: Some Observations
May 21, 2025 by
David S. Evans
Bolder by Design: Crafting Pro-Competitive Industrial Policies For Complex Challenges
May 21, 2025 by
Antonio Capobianco & Beatriz Marques
Competition-Friendly Industrial Policy
May 21, 2025 by
Philippe Aghion, Mathias Dewatripont & Patrick Legros